益肺灸治疗慢性阻塞性肺疾病稳定期临床疗效及对NF-κB/TGF-β1/Smad2信号通路影响  

Clinical Efficacy of Yifei Moxibustion in the Treatment of StableCOPD Patients and Its lmpact on the NF-kB/TGF-β1/Smad2 Signaling Pathway in Patients

作　　者：王湘雨[1] 王洋[1] 李亚[1] 李婷婷 王玮 WANG Xiangyu;WANG Yang;LI Ya;LI Tingting;WANG Wei(The First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450000,Henan,)

机构地区：[1]河南中医药大学第一附属医院,河南郑州450000

出　　处：《实用中医内科杂志》2024年第7期105-108,共4页Journal of Practical Traditional Chinese Internal Medicine

基　　金：河南省中医药科学研究专项(2019ZY1009)。

摘　　要：目的探讨益肺灸治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)稳定期临床疗效及对核因子κB(NF-κB)/转化生长因子-β1(TGF-β1)/Smad2信号通路影响。方法选择河南中医药大学第一附属医院于2022年1月—2024年1月COPD稳定期患者80例,按随机表法分为对照组与观察组40例。对照组常规西医治疗,观察组在对照组基础上结合益肺灸治疗。两组治疗周期3个月。比较两组临床疗效,急性加重次数和住院次数;治疗前后呼吸困难、6 min步行距离(6MWD)和生活质量,肺功能,血清NF-κB、TGF-β1和Smad2水平变化。结果观察组总有效率高于对照组(P<0.05)。观察组急性加重次数和住院次数均少于对照组(P<0.05)。两组治疗后MMRC评分和CAT评分低于治疗前,6MWD高于治疗前(P<0.05);观察组治疗后MMRC评分和CAT评分低于对照组,而6MWD高于对照组(P<0.05)。两组治疗后FVC和FEV_(1)/FVC高于治疗前(P<0.05);且观察组高于对照组(P<0.05)。两组治疗后血清NF-κB、TGF-β1和Smad2水平低于治疗前(P<0.05);且观察组低于对照组(P<0.05)。结论益肺灸治疗COPD稳定期临床疗效显著,其机制可能与下调NF-κB/TGF-β1/Smad2信号通路表达有关。Objective To explore the clinical efficacy of Yifei Moxibustion in the treatment of stable chronic obstructive pulmonary disease(COPD)patients and its impact on the nuclear factorκB(NF-κB)/transforming growth factor-β1(TGF-β1)/Smad2 signaling pathway in patients.Method From January 2022 to January 2024 in The First Affiliated Hospital of Henan University of Traditional Chinese Medicine stable COPD 80 patients divided control group 40 cases and observation group 40 cases.Control group western medicine treatment,observation group bassis of control group combined Yifei Moxibustion.The treatment period for two groups is 3 months.Compare the treatment efficacy,acute exacerbation frequency,and hospitalization frequency between two groups;Changes in breathing difficulties,6-minute walking distance(6MWD),quality of life,lung function,serum levels of NFB,TGF-β1,and Smad2 before and after treatment.Result The observation group effective rate of stable COPD patients higher control group(P<0.05).The observation group number of acute exacerbations and hospitalizations in stable COPD patient lower control group(P<0.05).After treatment,two groups MMRC score and CAT score of stable COPD patients lower before treatment,while the 6MWD score higher before treatment(P<0.05);observation group MMRC score and CAT score of stable COPD patients lower control group,while the 6MWD score higher control group(P<0.05).After treatment,two groups FVC and FEV_(1)/FVC of stable COPD patients higher before treatment(P<0.05);observation group FVC and FEV_(1)/FVC of stable COPD patients higher control group(P<0.05).After treatment,two groups serum levels of NF-κB,TGF-β1,and Smad2 in stable COPD patients lower before treatment(P<0.05);observation group serum levels of NF-κB,TGF-β1 and Smad2 in stable COPD patients lower control group(P<0.05).Conclusion Yifei Moxibustion has significant clinical efficacy in treating stable COPD patients,and its mechanism may be related to downregulating the expression of NF-κB/TGF-β1/Smad2 signaling pathway

关 键 词：益肺灸 慢性阻塞性肺疾病 稳定期 临床疗效 NF-κB/TGF-β1/Smad2 

分 类 号：R256.1[医药卫生—中医内科学]